Previous 10 | Next 10 |
Exelixis (EXEL) has enrolled the first patient into the dose-escalation cohort of the combination arm of the Phase 1 trial evaluating XL092 alone and in combination with Genentech's atezolizumab (TECENTRIQ) in patients with advanced solid tumors.Initiated in February 2019, the dose-esca...
– Promising findings featuring XL092, Exelixis’ next-generation oral tyrosine kinase inhibitor, recently presented at the 32 nd EORTC-NCI-AACR (ENA) Symposium – Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first patient int...
– Conference Call and Webcast to Follow at 5:00 p.m. EST / 2:00 p.m. PST – Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2020 financial results will be released on Thursday, November 5, 2020 after the markets close. At 5:00 p.m. EST /...
Under Priority Review status, the FDA has accepted supplemental marketing applications from Bristol-Myers Squibb (BMY) and Exelixis (EXEL) seeking approval to use the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) to treat advanced renal cell carcinoma ((RCC)).The agency's act...
U.S. Food and Drug Administration assigned a target action date of February 20, 2021 Applications based on pivotal Phase 3 CheckMate -9ER trial, which showed OPDIVO in combination with CABOMETYX improved overall survival, doubled median progression-free survival ...
Warren Buffett built a fortune over the past few decades. Hailed as the greatest contemporary investor, the "Oracle of Omaha" now, at the age of 90, has billions of dollars at his disposal to invest as the CEO of Berkshire Hathaway . But successful investing doesn't hinge on having acce...
Pfizer reports encouraging results for growth hormone deficiency trial. Dexcom collaborates with Lilly for diabetes management program. Exelixis and Aurigene reports positive data for cancer treatment AUR102. For further details see: Pfizer Reports Data, And Other News: ...
Exelixis (EXEL) and Aurigene Discovery Technologies Limited disclosed new preclinical data showing that AUR102, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7), has potent anti-tumor activity in a large panel of cancer cell lines with induction of...
– Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies – Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Techn...
– In preclinical studies, XL092 demonstrated robust target and tumor growth inhibition – – Clinical pharmacokinetic (PK) data suggest a significantly shorter half-life than cabozantinib – – Phase 1 evaluation of XL092 in...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...